Table 1.

Plasma Levels of ALT, AST, and Creatinine in Tumor-Bearing Mice to Determine the Effect of the 15d-PGJ₂ Treatment on Liver and Renal Toxicity.

Tumor Models	Treatment Groups	ALT (U/L)	AST (U/L)	AST/ALT Ratio	Creatinine (µM)
B16 tumor-bearing mice	PBS (n = 5)	44.4 ± 7.2	602 ± 60.2	14.5 ± 2.0	7.80 ± 0.97
	15d-PGJ2	35.2 ± 2.0	135 ± 20.1*	3.92 ± 0.6*	7.83 ± 1.0
C26 tumor-bearing mice	PBS	18.8 ± 1.4	67.8 ± 6.5	3.73 ± 0.5	8.0 ± 1.2
	15d-PGJ2	14.5 ± 1.7†	56.2 ± 6.4	4.14 ± 0.8	9.67 ± 1.4

ALT indicates alanine aminotransferase; AST, aspartate aminotransferase.

n = 6 animals per group unless mentioned.

^*P < .01, PBS versus 15d-PGJ₂.

^†P < .05, PBS versus 15d-PGJ₂.